- Acumen Powered by Robins Kaplan LLP®
- Affirmative Recovery
- American Indian Law and Policy
- Antitrust and Trade Regulation
- Appellate Advocacy and Guidance
- Business Litigation
- Civil Rights and Police Misconduct
- Class Action Litigation
- Commercial/Project Finance and Real Estate
- Corporate Governance and Special Situations
- Corporate Restructuring and Bankruptcy
- Domestic and International Arbitration
- Entertainment and Media Litigation
- Health Care Litigation
- Insurance and Catastrophic Loss
- Intellectual Property and Technology Litigation
- Mass Tort Attorneys
- Medical Malpractice Attorneys
- Personal Injury Attorneys
- Telecommunications Litigation and Arbitration
- Wealth Planning, Administration, and Fiduciary Disputes
Acumen Powered by Robins Kaplan LLP®
Ediscovery, Applied Science and Economics, and Litigation Support Solutions
-
December 2, 2024Robins Kaplan LLP Announces 2025 Partners
-
November 20, 2024Eighth Circuit Affirms U.S. Merchants Victory in Trade Dress Infringement Case
-
November 15, 2024Lauren Coppola Named an Emerging Leader by Profiles in Diversity Journal
-
December 11, 20242024 Year in Review: eDiscovery and Artificial Intelligence
-
December 12, 2024Strategies for Licensing AI: A Litigation Perspective
-
December 2024A Landmark Victory for Disabled Homeless Veterans: Q&A with the Trial Team
-
November 8, 2024Trademark tensions on the track: Court upholds First Amendment protections in Haas v. Steiner
-
November 8, 2024Destination Skiing And The DOJ's Mountain Merger Challenge
-
September 16, 2022Uber Company Systems Compromised by Widespread Cyber Hack
-
September 15, 2022US Averts Rail Workers Strike With Last-Minute Tentative Deal
-
September 14, 2022Hotter-Than-Expected August Inflation Prompts Massive Wall Street Selloff
Find additional firm contact information for press inquiries.
Find resources to help navigate legal and business complexities.
New ANDA Cases
2011/2012
Case Name | Date Filed | Judge | Drug | Patent No(s). |
---|---|---|---|---|
Eisai Inc. v. BannerPharmacapsInc., 11-901 (D. Del.) |
Oct. 4, 2011 |
Hon. Gregory M. Sleet |
Targretin®(bexarotine capsules) |
5,780,676 5,962,731 |
Pfizer Inc. v. Watson Pharma., Inc. , 11-914 (D. Del.) |
Oct. 6, 2011 |
Hon. Berle M. Schiller |
Embeda®(morphine sulfate/naltrexone hydrochloride extended-release capsules) |
7,682,633 7,682,634 7,815,934 |
Pfizer Inc. v. Watson Pharma., Inc. , 11-5860 (D.N.J.) |
Oct. 7, 2011 |
Hon. Claire C. Cecchi |
Embeda®(morphine sulfate/naltrexone hydrochloride extended-release capsules) |
7,682,633 7,682,634 7,815,934 |
Novartis Pharma. Corp. v. Alembic Pharma. Ltd. , 11-7092 (S.D.N.Y.) |
Oct. 7, 2011 |
Hon. Harold Baer |
Exelon®(rivastigmine tartrate capsules) |
5,602,176 |
Purdue Pharma L.P. v. Ranbaxy, Inc. , 11-7104 (S.D.N.Y.) |
Oct. 7, 2011 |
Hon. Sidney H. Stein |
OxyContin®(oxycodone hydrochloride extended release tablet) |
7,674,799 7,674,800 7,683,072 |
Senju Pharma. Co., Ltd. v. Hi-Tech Pharmacal Co., Inc. , 11-1059 (D. Del.) |
Oct. 11, 2011 |
Hon. Sue L. Robinson |
Zymaxid®(gatifloxacin ophthalmic solution, 0.5%) |
6,333,045 5,880,283 |
Warner Chilcott Co., LLC v. Watson Pharma., Inc. , 11-5989 (D.N.J.) |
Oct. 12, 2011 |
Hon. Faith S. Hochberg |
Atelvia®(risedronate sodium delayed release tablets) |
7,645,459 7,645,460 |
Noven Pharma., Inc. v. Watson Labs., Inc. , 11-5997 (D.N.J.) |
Oct. 13, 2011 |
Hon. Dennis M. Cavanaugh |
Daytrana® (methylphenidate transdermal patch) |
6,210,705 6,348,211 |
Schering Corp. v. Actavis Inc. , 11-6067 (D.N.J.) |
Oct. 13, 2011 |
Hon. Jose L. Linares |
Vytorin®(ezetimibe/simvastatin tablets) |
RE42,461 5,846,966 |
Alcon Pharma., Ltd. v. Perrigo Co. , 11-0732 (N.D. Tex. ) |
Oct. 14, 2011 |
Hon. Terry R. Means |
Patanase®(olopatadinehydrochloride nasal spray, 0.665%) |
7,977,376 |
Novo Nordisk Inc. v. SandozInc., 11-6106 (D.N.J.) |
Oct. 14, 2011 |
Hon. Freda L. Wolfson |
Prandin®(repaglinide tablets) |
6,677,358 |
Janssen Pharma., Inc. v. Sun Pharma Global FZE , 11-6089 (D.N.J.) |
Oct. 17, 2011 |
Hon. Stanley R. Chesler |
Ortho Tri-cyclen®LO (norgestimate/ethinyl estradiol tablets) |
6,214,815 |
Alkermes Pharma Ireland Ltd. v. Torrent Pharma. Ltd. , 11-1009 (D. Del.) |
Oct. 21, 2011 |
Hon. Gregory M. Sleet |
Luvox CR®(fluvoxamine maleate extended-release capsules) |
7,465,462 |
AstraZeneca AB v. AnchenPharma., Inc., 11-6348 (D.N.J.) |
Oct. 28, 2011 |
Hon. Joel A. Pisano |
Vimovo®(naproxen and esomeprazole magnesium delayed release tablets) |
6,926,907 6,369,085 7,411,070 7,745,466 |
Abbott Products, Inc. v. Perrigo Co. , 11-6357 (D.N.J.) |
Oct. 31, 2011 |
Hon. Freda L. Wolfson |
AndroGel®(testosterone gel) |
6,503,894 |
Senju Pharma. Co., Ltd. v. Hi-Tech Pharmacal Co., Inc. , 11-1059 (D. Del.) |
Oct. 31, 2011 |
Hon. Sue L. Robinson |
Zymar®(gatifloxacin ophthalmic solution, 0.3%)) |
6,333,045 5,880,283 |
Cephalon, Inc. v. Breckenridge Pharma., Inc. , 11-1070 (D. Del.) |
Nov. 2, 2011 |
Hon. Gregory M. Sleet |
Nuvigil®(armodifinil tablets) |
7,132,570 |
Cephalon, Inc. v. Breckenridge Pharma., Inc. , 11-6455 (D.N.J.) |
Nov. 3, 2011 |
Hon. Jose L. Linares |
Nuvigil®(armodifinil tablets) |
7,132,570 |
Novartis Pharma. Corp. v. Actavis South Atlantic LLC , 11-1077 (D. Del.) |
Nov. 3, 2011 |
Hon. Sue L. Robinson |
Exelon®Patch (rivastigmine transdermal system or extended release film) |
5,602,176 6,316,023 6,335,031 |
Novartis Pharma. Corp. v. Actavis South Atlantic LLC , 11-62371 (S.D. Fla. ) |
Nov. 4, 2011 |
Hon. William P. Dimitrouleas |
Exelon®Patch (rivastigmine transdermal system or extended release film) |
5,602,176 6,316,023 6,335,031 |
Celgene Corp. v. Actavis South Atlantic LLC , 11-6519 (D.N.J.) |
Nov. 4, 2011 |
Hon. Susan D. Wigenton |
Focalin®XR (dexmethylphenidate hydrochloride capsules) |
5,908,850 6,355,656 6,528,530 5,837,284 6,635,284 7,431,944 |
Alkermes Pharma Ireland Ltd. v. Actavis, Inc., 11-1098 (D. Del.) |
Nov. 4, 2011 |
Hon. Sue L. Robinson |
Focalin®XR (dexmethylphenidate hydrochloride capsules) |
6,228,398 6,730,325 |
Warner Chilcott Co., LLC v. Zydus Pharma.(USA) Inc., 11-1105 (D. Del.) |
Nov. 8, 2011 |
Hon. Richard G. Andrews |
Asacol®HD (mesalamine delayed-release oral tablet) |
6,893,662 |
Galderma Labs. Inc. v. AmnealPharma., LLC, 11-1106 (D. Del.) |
Nov. 8, 2011 |
Hon. Leonard P. Stark |
Oracea®(doxycycline delayed-release capsules) |
7,749,532 7,232,572 7,211,267 |
Cephalon, Inc. v. Mylan Pharma.Inc., 11-1111 (D. Del.) |
Nov. 9, 2011 |
Hon. Sue L. Robinson |
Fentora®(fentanyl buccal tablets) |
6,200,604 6,974,590 7,862,832 7,862,833 |
Novartis Pharma. Corp. v. Watson Labs. Inc. , 11-1112 (D. Del.) |
Nov. 9, 2011 |
Hon. Sue L. Robinson |
Exelon®Patch (rivastigmine transdermal system or extended release film) |
5,602,176 6,316,023 6,335,031 |
Abbott Labs. v. SandozInc., 11-1113 (D. Del.) |
Nov. 9, 2011 |
Hon. Sue L. Robinson |
Simcor®(niacin extended release/simvastatin tablets) |
6,080,428 6,469,035 |
Reckitt Benckiser LLC v. Amneal Pharma. LLC , 11-6609 (D.N.J.) |
Nov. 9, 2011 |
Hon. Joel A. Pisano |
Delsym®(dextromethorphan polistirex extended release liquid suspension) |
5,980,882 |
Novartis Pharma.Corp. v. Watson Labs. Inc. , 11-8130 (S.D.N.Y.) |
Nov. 10, 2011 |
Hon. Harold Baer |
Exelon®Patch (rivastigmine transdermal system or extended release film) |
5,602,176 6,316,023 6,335,031 |
Purdue Pharma L.P. v. Amneal Pharma., L.L.C. , 11-8153 (S.D.N.Y.) |
Nov. 10, 2011 |
Hon. Sidney H. Stein |
OxyContin®(oxycodone hydrochloride extended release tablet) |
7,674,799 7,674,800 7,683,072 7,776,314 |
Celgene Corp. v. ParPharma., Inc., 11-6640 (D.N.J.) |
Nov. 10, 2011 |
Hon. Susan D. Wigenton |
Focalin®XR (dexmethylphenidate hydrochloride capsules) |
5,908,850 6,355,656 6,528,530 5,837,284 6,635,284 7,431,944 |
Alkermes Pharma Ireland Ltd. v. ParPharma., Inc., 11-1119 (D. Del.) |
Nov. 11, 2011 |
Hon. Sue L. Robinson |
Focalin®XR (dexmethylphenidate hydrochloride capsules) |
6,228,398 6,730,325 |
Allergan, Inc. v. LupinLtd., 11-611 (E.D. Tex.) |
Nov. 11, 2011 |
Hon. Michael H. Schneider |
Lumigan®(bimatoprost ophthalmic solution 0.01%) |
7,851,504 |
Aventis Pharma S.A. v. Strides, Inc., 11-1121 (D. Del.) |
Nov. 14, 2011 |
Hon. Gregory M. Sleet |
Taxotere®(docetaxel injection) |
5,714,512 5,750,561 |
Takeda Pharma. Co. Ltd. v. HeteroDrugsLtd., 11-8302 (S.D.N.Y.) |
Nov. 16, 2011 |
Hon. Denise L. Cote |
Actos®(pioglitazone hydrochloride tablets) |
5,965,584 6,329,404 6,166,043 |
Cephalon, Inc. v. ImpaxLabs., Inc., 11-1152 (D. Del.) |
Nov. 18, 2011 |
Hon. Sue L. Robinson |
Fentora®(fentanyl buccaltablets) |
6,200,604 6,974,590 7,862,832 7,862,833 |
The Medicines Co. v. Sun Pharma Global FZE , 11-6819 (D.N.J.) |
Nov. 21, 2011 |
Hon. Peter G. Sheridan |
Angiomax®(bivalirudin intravenous injection) |
7,582,727 7,598,343 |
Warner Chilcott Co., LLC v. Mylan Inc. , 11-6844 (D.N.J.) |
Nov. 22, 2011 |
Hon. Joel A. Pisano |
Generess™ Fe (norethindrone and ethinyl estradiol chewable tablet) |
6,667,050 |
Warner Chilcott Co., LLC v. Teva Pharma. USA Inc. , 11-6936 (D.N.J.) |
Nov. 22, 2011 |
Hon. Faith S. Hochberg |
Atelvia®(risedronate sodium delayed release tablets) |
7,645,459 7,645,460 |
Bristol-Myers Squibb Co. v. Apotex Inc. , 11-6918 (D.N.J.) |
Nov. 23, 2011 |
Hon. Mary L. Cooper |
Sprycel®(dasatinib tablet) |
6,596,746 7,125,875 7,153,856 7,491,725 |
The Medicines Co. v. Sun Pharma Global FZE , 11-15175 (E.D. Mich.) |
Nov. 23, 2011 |
Hon. Bernard A. Friedman |
Angiomax®(bivalirudin intravenous injection) |
7,582,727 7,598,343 |
Ferring B.V. v. Watson Pharma., Inc. , 11-853 (D. Nev.) |
Nov. 25, 2011 |
Hon. Larry R. Hicks |
Lysteda®(tranexamic acid tablets) |
8,022,106 |
Ferring B.V. v. Apotex, Inc. , 11-854 (D. Nev.) |
Nov. 25, 2011 |
Hon. Larry R. Hicks |
Lysteda®(tranexamic acid tablets) |
8,022,106 |
Senju Pharma. Co., Ltd. v. ApotexInc., 11-1171 (D. Del.) |
Nov. 28, 2011 |
Hon. Sue L. Robinson |
Zymaxid®(gatifloxacin ophthalmic solution, 0.5%) |
6,333,045 |
Alkermes Pharma Ireland Ltd. v. Teva Pharma. USA Inc., 11-1186 (D. Del.) |
Dec. 1, 2011 |
Hon. Sue L. Robinson |
Focalin®XR (dexmethylphenidate hydrochloride capsules) |
6,228,398 6,730,325 |
Abbott Labs. v. Sun Pharma. Indus. Ltd. , 11-1190 (D. Del.) |
Dec. 2, 2011 |
Hon. Sue L. Robinson |
Niaspan®(niacin extended release tablet) |
6,129,930 6,406,715 6,676,967 6,746,691 6,818,229 7,011,848 |
Abbott Labs. v. Wockhardt, Ltd. , 11-7046 (D.N.J.) |
Dec. 2, 2011 |
Hon. Dennis M. Cavanaugh |
Tricor®(fenofibrate tablet) |
6,277,405 7,037,529 7,041,319 |
Alkermes Pharma Ireland Ltd. v. Wockhardt, Ltd. , 11-7047 (D.N.J.) |
Dec. 2, 2011 |
Hon. Jose L. Linares |
Tricor®(fenofibrate tablet) |
7,276,249 7,320,802 |
Celgene Corp. v. Teva Pharma. USA, Inc. , 11-7064 (D.N.J.) |
Dec. 2, 2011 |
Hon. Susan D. Wigenton |
Focalin®XR (dexmethylphenidate hydrochloride capsules) |
5,908,850 6,355,656 6,528,530 5,837,284 6,635,284 7,431,944 |
Pfizer Inc. v. AlembicLtd, 11-1213 (D. Del.) |
Dec. 7, 2011 |
Hon. Gregory M. Sleet |
Lyrica®(pregabalin capsules) |
6,197,819 |
Alza Corp. v. MylanPharmaInc., 11-7158 (D.N.J.) |
Dec. 8, 2011 |
Hon. Esther Salas |
Glucotrol®XL (glipizide extended release tablets) |
5,591,454 |
Warner Chilcott Co. LLC v. Lupin Ltd. , 11-7228 (D.N.J.) |
Dec. 12, 2011 |
Hon. Joel A. Pisano |
Generess™ Fe (norethindrone and ethinyl estradiol chewable tablet) |
6,667,050 |
Janssen Pharma. Inc. v. Sandoz, Inc. , 11-7247 (D.N.J.) |
Dec. 13, 2011 |
Hon. Freda L. Wolfson |
Doribax®(doripenem injection) |
5,317,016 |
Cephalon, Inc. v. Celgene Corp. , 11-12226 (D. Mass.) |
Dec. 14, 2011 |
Hon. George A. O’Toole, Jr. |
Abraxane®(paclitaxelinjection) |
RE40,493 |
Pfizer Inc. v. Sandoz Inc. , 11-1252 (D. Del.) |
Dec. 15, 2011 |
Hon. Gregory M. Sleet |
Torisel®(temsirolimus injection) |
5,362,718 |
Pfizer Inc. v. Intas Pharma. Ltd. , 11-1253 (D. Del.) |
Dec. 15, 2011 |
Hon. Leonard P. Stark |
Torisel®(temsirolimus injection) |
5,362,718 |
Shire LLC v. Mylan Pharma. Inc. , 11-0201 (N.D. W. Va. ) |
Dec. 15, 2011 |
Hon. Irene M. Keeley |
Intuniv®(guanfacine hydrochloride extended-release tablets) |
6,287,599 6,811,794 5,854,290 |
Roche Palo Alto LLC v. Dr.Reddy’sLabs., Ltd., 11-1264 (D. Del.) |
Dec. 20, 2011 |
Hon. Gregory M. Sleet |
Valcyte®(valganciclovir hydrochloride) |
6,083,953 |
Allergan, Inc. v. Akorn, Inc. , 11-1270 (D. Del.) |
Dec. 21, 2011 |
Hon. Christopher J. Burke |
Acuvail®(ketorolac tromethamine ophthalmic solution, 0.45%) |
7,842,714 |
MSD Consumer Products, Inc. v. Zydus Pharma. (USA) Inc., 11-7437 (D.N.J.) |
Dec. 21, 2011 |
Hon. Peter G. Sheridan |
Zegerid OTC™ (omeprazole/sodium bicarbonate capsules) |
6,699,885 6,489,346 6,645,988 7,399,772 |
Santarus, Inc. v. ZydusPharma.(USA) Inc., 11-7441 (D.N.J.) |
Dec. 21, 2011 |
Hon. Peter G. Sheridan |
Zegerid Rx™ (omeprazole/sodium bicarbonate capsules) |
6,699,885 6,489,346 6,645,988 7,399,772 |
GlaxoSmithKline Intellectual Property Management Ltd. v. Sandoz, Inc. , 11-1284 (D. Del.) |
Dec. 23, 2011 |
Hon. Richard G. Andrews |
Veramyst®(fluticasone fuorate metered nasal spray) |
6,858,596 7,101,866 7,541,350 |
Merck Frosst Canada & Co. v. Mylan Pharma. Inc. , 11-7569 (D.N.J.) |
Dec. 29, 2011 |
Hon. Freda L. Wolfson |
Singulair®(montelukast sodium oral granules eq. to 4 ml base/packet) |
8,007,830 |
Allergan, Inc. v. Lupin Ltd. , 11-0530 (E.D. Tex.) |
Dec. 30, 2011 |
Hon. David Folsom |
Acular LS®(ketorolac tromethamine ophthalmic solution, 0.4%) |
8,008,338 |
Related Publications
Related News
If you are interested in having us represent you, you should call us so we can determine whether the matter is one for which we are willing or able to accept professional responsibility. We will not make this determination by e-mail communication. The telephone numbers and addresses for our offices are listed on this page. We reserve the right to decline any representation. We may be required to decline representation if it would create a conflict of interest with our other clients.
By accepting these terms, you are confirming that you have read and understood this important notice.